Diagnostics of neuroendocrine tumours

In Vivo

Volumn 24, Issue 5, 2010, Pages 771-774

  Hodolic M ^a   Fettich, J ^a   Banti, E ^b   Chondrogiannis, S ^b   Al Nahhas, A ^c   Rubello, Domenico ^b  

^a UNIVERSITY MEDICAL CENTRE LJUBLJANA   (Slovenia)

^b SANTA MARIA DELLA MISERICORDIA HOSPITAL   (Italy)

^c HAMMERSMITH HOSPITAL   (United Kingdom)

Author keywords

Diagnosis; Neuroendocrine tumours; PET DOTA peptides; Scintigraphy; Short review; Somatostatin

Indexed keywords

(3 IODOBENZYL)GUANIDINE I 123; 1,4,7,10 TETRAAZACYCLODODECANE 1,4,7,10 TETRAACETIC ACID; 5 HYDROXYINDOLEACETIC ACID; 5 HYDROXYTRYPTOPHAN; 6 FLUORODOPA F 18; BIOLOGICAL MARKER; CARBIDOPA; CARBON 11; CHROMOGRANIN A; DOPAMINE DERIVATIVE; FLUORODEOXYGLUCOSE F 18; GALLIUM 68; GASTRIN; GLUCAGON; INSULIN; KI 67 ANTIGEN; NEURON SPECIFIC ENOLASE; OCTREOTIDE; PENTETREOTIDE; PENTETREOTIDE IN 111; RADIOPHARMACEUTICAL AGENT; SEROTONIN; SOMATOSTATIN; SOMATOSTATIN RECEPTOR 1; SOMATOSTATIN RECEPTOR 2; SOMATOSTATIN RECEPTOR 3; SOMATOSTATIN RECEPTOR 4; SOMATOSTATIN RECEPTOR 5; TUMOR MARKER; VASOACTIVE INTESTINAL POLYPEPTIDE;

ARTERIOGRAPHY; CANCER DIAGNOSIS; CANCER LOCALIZATION; CARCINOID; CAROTID BODY TUMOR; COLOR ULTRASOUND FLOWMETRY; COMPUTER ASSISTED TOMOGRAPHY; CONTRAST ENHANCEMENT; DIAGNOSTIC ACCURACY; DRUG EXCRETION; DRUG UPTAKE; ENDOSCOPIC ECHOGRAPHY; ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY; GASTRIN BLOOD LEVEL; GASTRINOMA; HISTOPATHOLOGY; HUMAN; INSULINOMA; ISOTOPE LABELING; LYMPH NODE METASTASIS; MAGNETIC RESONANCE CHOLANGIOPANCREATOGRAPHY; MELANOMA; NEUROBLASTOMA; NEUROENDOCRINE TUMOR; NUCLEAR MAGNETIC RESONANCE IMAGING; PHEOCHROMOCYTOMA; POSITRON EMISSION TOMOGRAPHY; PROTEIN EXPRESSION; RECURRENT CANCER; REVIEW; SENSITIVITY AND SPECIFICITY; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; THORAX RADIOGRAPHY; THYROID MEDULLARY CARCINOMA; WHOLE BODY SCINTISCANNING;

EID: 78649341427     PISSN: 0258851X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (33)

1. Ferolla P, Faggiano A, Mansueto G et al: The biological characterization of neuroendocrine tumors: the role of neuroendocrine markers; J Endocrinol Invest 31(3): 277-286, 2008
2. Grand CS: Gastrointestinal endocrine tumours. Insulinoma. Baillieres Clin Gastroenterol 10: 645-671, 1996.
3. Zollinger RM and Ellison EH: Primary peptic ulcerations of the jejunum associated with islet cell tumours of the pancreas. Ann Surg 142: 709-728, 1955.
4. Solcia E, Kloppel G and Sobin LH: Histological Typing of Endocrine Tumours. WHO International Classification of Tumours. Berlin: Springer pp. 1-149, 1999.
5. Capella C, Heitz PU, Höfler H et al: Revised classification of neuroendocrine tumours of the lung, pancreas and gut. Digestion 55(suppl 3): 11-23, 1994.
6. Öberg K and Stridsberg M: Chromogranins as diagnostic and prognostic markers in neuroendocrine tumours. Adv Exp Med Biol 482: 329-337, 2000.
7. Johnson DH, Marangos PJ, Forbes JT et al: Potential utility of serum neuron-specific enolase levels in small cell carcinoma of the lung. Cancer Res 44(11): 5409-5414, 1984.
8. Anastasiades KD, Mullins RE and Conn RB: Neuron-specific enolase: assessment by ELISA in patients with small cell carcinoma of the lung. Am J Clin Pathol 87(2): 245-249, 1987.
9. Akoun GM, Scarna HM, Milleron BJ et al: Serum neuron-specific enolase. A marker for disease extent and response to therapy for small cell lung cancer. Chest 87(1): 39-43, 1985.
10. Thompson RJ, Doran JF, Jackson P et al: PGP 9.5 - a new marker for vertebrate neurons and neuroendocrine cells. Brain Res 14:278(1-2): 224-228, 1983.
11. Hall PA and Levison DA: Assessment of cell proliferation in histologic material. J Clin Pathol 43(3): 184-192, 1990.
12. Reubi JC: Clinical relevance of somatostin receptor imaging. Eur J Nucl Med 131: 575-576, 1994.
13. D'Onofrio M, Mansueto G, Falconi M et al: Neuroendocrine pancreatic tumor: value of contrast enhanced ultrasonography. Abdom Imaging 29: 246-258, 2004.
14. Khan S, Lloyd C, Syszko T et al: PET imaging in endocrine tumours. Minerva Edocrinologica 33(2): 41-52, 2008.
15. Grenacher L and Klauss M: Computed tomography of pancreatic tumors. Radiologe 49(2): 107-123, 2009.
16. Reznek R: CT/MRI of neuroendocrine tumours. Cancer Imaging; 6: 163-177, 2006.
17. Schillaci O, Scopinaro F, Angeletti S et al: SPECT improves accuracy of somatostatin receptors scintigraphy in abdominal carcinoids tumours. J Nucl Med 37: 1452-1456, 1996.
18. Wagner C, Kaplan SR and Tannenbaum GS: Interactions of ghrelin signaling pathways with the GH neuroendocrine axis: a new and experimentally tested model. J Mol Endocrinol 43(3): 105-119, 2009.
19. Reubi JC, Laissue J, Krenning E et al: Somatostatin receptors in human cancer: incidence, characteristic, functional correlates and clinical implications. J Steroid Biochem Mol Biol 43: 27-35, 1992.
20. Reubi JC, Kvols L, Krennig E et al: Distribution of somatostatin receptors in normal and tumours tissue. Metabolism 39: 78-81, 1990.
21. 99mTc-EDDA/HYNIC- TOC somatostatin receptor scintigraphy in daily clinical practice. Med Sci .Monit 16(4): MT 35-44, 2010
22. Hanson MW: Scintigraphic evaluation of neuroendocrine tumours. Applied Radiology 30: 11-17, 2001.
23. 99mTc-EDDA/HYNIC-TOC). J Label Compd Radiopharm 46: 307-318, 2003.
24. 111In-DTPA-octreotide uptake in patients without known pathology. Eur J Nucl Med Mol Imaging 31(suppl 2): 358 (abs), 2004.
25. 18F)fluoro3,4-diihydroxy-L- phenylalanine accumulation in neuroendocrine tumors cells. Cancer Res 68(17): 7183-7190, 2008.
26. 18F-FDG in metastatic medullary thyroid carcinoma and rapidly increasing calcitonin levels: comparison with conventional imaging. Eur J Surg Oncol 36(4): 414-421, 2010
27. 68Ga-DOTA-TATE. Eur J Nucl Med Mol Imaging 37(10): 2004-2010, 2010.
28. 18F-DOPA PET for detection of gastrointestinal carcinoid tumours. Radiology 220: 373-380, 2001.
29. 111In-pentetreotide negative GEP tumours. Nucl Med Commun 25: 473-477, 2007.
30. 11C-5- hydroxytryptophan positron-emission tomography. Eur J Nucl Med Mol Imaging 33: 60-65, 2006. (Pubitemid 41785310)
31. Khan S, Lloyd C, Syszko T et al: PET imaging in endocrine tumours. Minerva Edocrinologica 33(2): 41-52, 2008.
32. Al-Nahhas A, Win Z, Szyszko T et al: Gallium-68 PET: a new frontier in receptor cancer imaging. Anticancer Res 27: 4087-4094, 2007.
33. 68Ga-DOTA-Tyr3- octreotide PET in neuroendocrine tumours: comparison with somatostatin receptor scintigraphy and CT. J Nucl Med 48: 508-518, 2007.